Gilead, Teva reach settlement in Viread patent lawsuit

A sign bearing the logo of Teva is seen in Jerusalem(Reuters) – Gilead Sciences Inc said it has agreed with Israel's Teva Pharmaceuticals Industries Ltd to settle a lawsuit relating to patents protecting Viread, a treatment for HIV infection and chronic hepatitis B. As per the agreement, Gilead said Teva will be allowed to launch a generic version of Viread on December 15, 2017. "This settlement removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation," Gilead's chief operating officer, John Milligan, said in a statement late on Tuesday. …



Sexual Health News Headlines – Yahoo! News